Nobody likes the grammar police. Patent lawyers, unfortunately, may be the exception.
In Enanta Pharmaceuticals, Inc. v. Pfizer Inc. No. 2025-1427 (Fed. Cir. June 23, 2026), one character did a lot of damage. The difference between C2 and C1 cost Enanta the priority date of its provisional application—and led the Federal Circuit to affirm that the challenged claims were anticipated.
Turns out proofreading really can be worth millions.
But the case raises a more interesting question: Even if Enanta had … Read the rest